Based on our results and the above mentioned recent published data, we believe that treatment of tamoxifen resistant breast cancer with a functional ER should be a combination of fulvestrant and an ER-independent kinase inhibitor or by tamoxifen in combination with a kinase inhibitor targeting ER activation as well as other important growth promoting pathways. Here, ESR1 is linked to breast carcinoma.